Prosecution Insights
Last updated: November 04, 2026
Application No. 18/677,117

DETECTION OF DRUG RESISTANCE OF MICROORGANISMS

Non-Final OA §112
Filed
May 29, 2024
Priority
Mar 01, 2017 — provisional 62/465,691 +1 more
Examiner
VAN BUREN, LAUREN K
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Specific Technologies LLC
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
170 granted / 425 resolved
-20.0% vs TC avg
Strong +58% interview lift
Without
With
+58.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
47 currently pending
Career history
479
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
49.6%
+9.6% vs TC avg
§102
10.1%
-29.9% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 425 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-13 are under examination. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventors, at the time the application was filed, had possession of the claimed invention. Claim 1 recites that any sample with a microorganism without containing an antibiotic can be analyzed in order to determine whether or not the microorganism is resistant to that particular antibiotic. The specification fails to describe an adequate number of microorganism species that are capable of defining the claimed genus of a sample containing a microorganism in a medium without antibiotics. The specification fails to describe an adequate number of antibiotic species that are capable of defining the claimed genus of at least one antibiotic. “[T]he purpose of the written description requirement is to ‘ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor's contribution to the field of art as described in the patent specification.” Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1353-54 (Fed. Cir. 2010) (en banc) (quoting Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 920 (Fed. Cir. 2004)). “To satisfy the written description requirement, the specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention.” Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1562-63, 19 USPQ2d 1111 (Fed. Cir. 1991). See also MPEP 2163.04. A described in MPEP § 2163, “The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice...reduction to drawings...or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus”...See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A "representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014) (Claims directed to a functionally defined genus of antibodies were not supported by a disclosure that "only describe[d] one type of structurally similar antibodies" that "are not representative of the full variety or scope of the genus." The first genus is a microorganism present in a sample that is analyzed for susceptibility or resistance. Another genus is the antibiotic. In analyzing whether the written description requirement is met for the genus, the specification is first assessed to determine whether a representative number of species of the genus have been described so that one is able to comprehend the structure of each genus. The specification must make it clear what the variations in the genus are. Applicants’ specification states that this method can be used successfully on E. Coli, Staphylococcus aureus, Klebsiella pneumonia bacteria strains where the resistance and susceptibility colorimetric sensor array patterns of each strain are known and identified. Furthermore, the specification only identifies that resistance and/or susceptibility to an antibiotic can only be determined when the antibiotic is carbapenem or methicillin as discussed in the working examples. Conclusion: Applicant only discloses in the working examples of the specification that the resistance to an antibiotic using colorimetric detection can be determined for E. Coli, Staphylococcus, Klebsiella pneumonia when the antibiotic is either carbapenem or methicillin. The claimed invention as a whole is not adequately described if the claims require essential or critical elements which are not adequately described in the specification, and are not conventional in the art as of Applicants’ effective filing date. Possession may be shown by actual reduction to practice, clear depiction of the claimed invention in a detailed drawing, or by describing the invention with sufficient, relevant, identifying characteristics (as it relates to the claimed invention as a whole), such that one of skill in the art would recognize that the inventor had possession of the claimed invention. Pfaff v. Wells Electronics, Inc., 48 USPQ2d 1641, 1646 (1998). In the instant case, the breath of the genus lacks a written description. To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. One cannot describe what one has not conceived. See Fiddes v. Baird, 30 USPQ2d 1481, 1483. In Fiddes, claims directed to mammalian FGFs were found to be unpatentable due to lack of written description for that broad class. The specification only provided the bovine sequence. Enablement Rejection Claims 1-13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The instant invention is not enabled for determining antibiotic resistance of a microorganism within a test sample using a colorimetric sensor array, a detection device, and a comparison library without the presence of at least one antibiotic in a test sample. Nor is the invention enabled for multi-drug resistance detection (Claim 2). The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosure in the application coupled with information known in the art without undue experimentation (United States v. Telectronics, Inc. 8 USPQD 2d 1217 (Fed. Cir. 1988). Whether undue experimentation is required is a conclusion reached by weighing several factors. These factors were outlined in Ex parte Forman, 230 USPQ 546 (Bd. Pat. App. & Inter. 1986) and again in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1998). While determining whether a specification is enabled, one considers whether the claimed invention provides sufficient guidance to make and use the claimed invention, if not, whether an artisan would require undue experimentation to make and use the claimed invention and whether working examples have been provided. When determining whether a specification meets the enablement requirements, some of the factors that need to be analyzed are: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill, the level of predictability in the art, the amount of direction provided by the inventor, the existence of working examples, and whether the quantity of any necessary experiment to make and use the invention based on the content of the disclosure is undue. Nature of the Invention: The claims recite that a sample containing a microorganism is cultured in a medium without antibiotics and various volatile organics compounds produced by the microorganism come into contact with a colorimetric sensory array. A detector can detect a color change that occurs in the colorimetric sensor array when its sensors are exposed to the volatile organic compounds produced by the microorganism. The color change of the colorimetric sensor array is compared to a stored library of color response changes/patterns stored within a computer to determine whether the microorganism in a sample has resistance to at least one antibiotic. Breadth of the Claims: The claims recite that the colorimetric sensor array/detector/computer system is able to detect in advance whether a sample with a microorganism is resistant to an antibiotic without including and comparing a control that includes the microorganism in the presence of the antibiotic. Claims 1 and 2 also recite that multi-drug resistance can also be detected. Teachings from the Prior Art: Lim (US 20150099694) states in paragraph 67 that, “To detect a microorganism by species and strain, a sample including microorganism is placed in a container including culture medium and colorimetric array, and the temporal response of the sensors to the metabolic products of the microorganism is monitored. Susceptibility can be assessed by inoculating a growth medium including a substance (e.g. an antibiotic) with a microorganism and monitoring the temporal response of the sensors while also monitoring the response of a control (e.g. no antibiotic).” In order for Lim’s system to work, the volatile organic compound results of a microorganism exposed to an antibiotic must be compared with a control that studies volatile organic compounds produced by a microorganism not exposed to an antibiotic. The system requires that both results must be able to be compared to determine if the strain is resistant or susceptible. Only one antibiotic is studied at a time, not multiple. Applicants Specification/Guidance/Working Examples: There specification provides no evidence that any microbe always produces a different volatile organic compound profile/pattern based on resistance/susceptibility to a particular antibiotic. There is no evidence that illustrates that resistance/susceptibility to each distinct antibiotic produces a unique profile of volatile organic compounds produced which results in a unique color pattern detected. The working examples of the specification state that the colorimetric array profiles/color changes of susceptible bacteria are compared to resistant bacteria of the same strain. Both the resistant and susceptible bacteria are from the same genus/species. For example, working Example 1 compares Carbapenem resistant E. Coli to Carbapenem susceptible E. Coli. Furthermore, working Example 2 compares methicillin resistant Staph aureus strains to methicillin susceptible Staph aureus strains. Working example 3 compares Klebsiella pneumonia strains that are resistant to carbapenem to Klebsiella pneumonia strains susceptible to carbapenem. Example 4 compares E. coli strains that are resistant to carbapenem to E. Coli strains that are susceptible to carbapenem. According to these examples, the specific strains are identified and the antibiotic is known. These examples have only one microorganism present and only study resistance/susceptibility to one antibiotic. In this case, the antibiotic is known and so is the species strain when the comparison of the colorimetric array patterns/changes based on the volatile organics occurs. This is distinct from the instant set of claims which state that a colorimetric sample/detector can be used to analyze any sample containing at least one microorganism without antibiotic/s and can successfully determine whether or not the microorganism is resistant to any antibiotic or multiple antibiotics (claim 2). The antibiotic can be any antibiotic and is not limited to methicillin or carbapenem. Conclusion: In order for the system to effectively distinguish antibiotic resistant strains from susceptible strains, there must be a comparison between a resistant and susceptible strain of the same genus/species as taught in the specification or a comparison between a sample containing only a microorganism and a sample containing a microorganism and an antibiotic. These types of comparisons are not mentioned in the instant claims. Therefore, it would be impossible to gage what is considered resistant to an antibiotic and what is considered susceptible to an antibiotic. Instead the instant claims state that the colorimetric sensory/detection system can determine antibiotic resistance just by the colorimetric sensor array and detector analyzing what volatile organic compounds are produced by one strain type without any type of control. Neither the claims nor the specification provided insight on how to determine whether the microorganism is resistant to just one antibiotic or multiple antibiotics. Conclusion The claims stand rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN K VAN BUREN whose telephone number is (571)270-1025. The examiner can normally be reached M-F:9:30am-5:40pm; 9:00-10:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. LAUREN K. VAN BUREN Examiner Art Unit 1638 /Tracy Vivlemore/Supervisory Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

May 29, 2024
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12775005
KETONE BODY SENSING DEVICE AND METHOD
6y 1m to grant Granted Oct 27, 2026
Patent 12773437
ONCOLYTIC VIRUSES AND METHODS FOR USING ONCOLYTIC VIRUSES
5y 2m to grant Granted Oct 27, 2026
Patent 12760267
ORGANOID ARRAYS
7y 7m to grant Granted Oct 13, 2026
Patent 12741026
Microparticle-Assisted Treg Therapy for Treatment of Tissue Injury and Fibrosis
3y 11m to grant Granted Sep 22, 2026
Patent 12703853
METHOD FOR CULTIVATION OF CARTILAGE AND SPHEROIDS THEREOF
4y 8m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
98%
With Interview (+58.4%)
4y 2m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 425 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month